Work

Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ( 90 Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL)

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.6574

Authors: L. I. Gordon, A. Molina, C. Emmanouilides, A. Raubitschek, M. Darif, R. J. Schilder, G. A. Wiseman, C. A. White, T. E. Witzig

Institutions: Northwestern University, Fox Chase Cancer Center, Biogen (United States), City Of Hope National Medical Center, Mayo Clinic, University of California, Los Angeles

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2595576200

Cites:

Cited by: 2

Related to: 10